AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis

Carcinogenesis

Volumn 23, Issue 1, 2002, Pages 201-205

  Roy, Hemant K ^d   Olusola, Bola F ^e   Clemens, Dahn L ^a   Karolski, William J ^a   Ratashak, Anne ^a   Lynch, Henry T ^b   Smyrk, Thomas C ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; ISOPROTEIN; MICROSATELLITE DNA; MONOCLONAL ANTIBODY; ONCOPROTEIN; POLYCLONAL ANTIBODY; PROTEIN KINASE B; SERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; COLON MUCOSA; COLON POLYP; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTESTINE CELL; MISMATCH REPAIR; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; RAT; RECEPTOR UPREGULATION;

EID: 0036195196     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/23.1.201     Document Type: Article

References (30)

1. Lessons from hereditary colorectal cancer
2. The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis
3. Identifying hereditary nonpolypsis colorectal cancer
4. Linking colorectal cancer to Wnt signaling
5. Cellular survival: A play in three Akts
6. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
7. Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone
8. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas
9. Cellular signaling: Pivoting around PDK-1
10. Akt oncogene in ovarian and breast carcinomas
11. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation
12. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers
13. Colorectal carcinoma in mice lacking catalytic subunit of PI(3)Kgamma
14. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression
15. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA
16. Serine/threonine protein kinases and apoptosis
17. Akt is more than just a Bad kinase
18. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein
19. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway
20. Epidermal growth factor impairs the cytochrome C/Caspase-apoptotic pathway induced by transforming growth factor beta in rat fetal hepatocytes via a phosphoinositide 3-kinase-dependent pathway
21. Akt regulates cell survival and apoptosis at a postmitochondrial level
22. Akt participation in the Wnt Signaling pathway through Dishevelled
23. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
24. Phosphorylation and regulation of Raf by Akt (protein kinase B)
25. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells
26. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells
27. Akt takes centre stage in cell-cycle deregulation
28. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
29. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis blocking Akt activation in human prostate cancer cells independently of Bcl-2
30. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis